Actively Recruiting
PRospective phenotypIng and Multi-omic Endotyping of Progressive Pulmonary Fibrosis
Led by University of Massachusetts, Worcester · Updated on 2025-09-22
500
Participants Needed
13
Research Sites
239 weeks
Total Duration
On this page
Sponsors
U
University of Massachusetts, Worcester
Lead Sponsor
U
University of Michigan
Collaborating Sponsor
AI-Summary
What this Trial Is About
This is a prospective, observational cohort study. Participants with non-idiopatic pulmonary fibrosis, interstitial lung disease (ILD) will be followed for 24 months to systematically collect clinical, imaging, and biospecimen data. The primary objective is to optimize progressive pulmonary fibrosis (PPF) classification and establish PPF incidence for key ILD subtypes. Additional exploratory objectives are to 1) Prospectively validate a novel PPF classifier and assess performance durability over time, and 2) Determine whether multi-dimensional PPF prediction outperforms component approaches.
CONDITIONS
Official Title
PRospective phenotypIng and Multi-omic Endotyping of Progressive Pulmonary Fibrosis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18-80 years with a diagnosis of non-IPF fibrosing ILD due to CTD-ILD, fHP, or non-IPF IIP based on central review
- Diagnosis of fibrotic ILD as determined by site investigator
- Willingness to comply with study procedures and follow-up
- Provide written informed consent
You will not qualify if you...
- Fibrosing ILD diagnosed more than 5 years before screening and baseline visit
- Minimal ILD affecting less than 5% of the lung without architectural distortion on HRCT
- Emphysema covering more than 15% of total lung volume or greater than fibrosis extent on HRCT
- Active malignancy within one year before screening except non-melanoma skin cancer requiring local treatment
- Inability to complete full pulmonary function tests at screening
- Taking nintedanib or nerandomilast at screening
- Pregnancy at screening or plans to become pregnant during follow-up
- Participation in an interventional fibrotic ILD clinical trial or investigational drug use within 4 weeks or 5 times the drug half-life before enrollment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 13 locations
1
University of Massachusetts Chan Medical School
Worcester, Massachusetts, United States, 01655
Actively Recruiting
2
University of Michigan
Ann Arbor, Michigan, United States, 48109
Actively Recruiting
3
University of Texas Southwestern
Dallas, Texas, United States, 75390
Not Yet Recruiting
4
University of Virginia
Charlottesville, Virginia, United States, 22908
Not Yet Recruiting
5
University of Washington
Seattle, Washington, United States, 98195
Not Yet Recruiting
6
Royal Prince Alfred Hospital
Camperdown, New South Wales, Australia, 2050
Not Yet Recruiting
7
Prince Charles Hospital
Brisbane, Queensland, Australia, 4032
Not Yet Recruiting
8
Austin Health
Melbourne, Victoria, Australia, 3000
Not Yet Recruiting
9
University of Calgary
Calgary, Alberta, Canada, T2N 4Z6
Not Yet Recruiting
10
University of British Columbia
Vancouver, British Columbia, Canada, V6Z 1Y6
Not Yet Recruiting
11
University College Dublin
Dublin, Ireland, Ireland, D04 T6F4
Not Yet Recruiting
12
Royal Brompton
London, Greater London, United Kingdom, SW3 6NP
Not Yet Recruiting
13
University Hospital Southampton
Southampton, Hampshire, United Kingdom, SO16 7DL
Not Yet Recruiting
Research Team
F
Fernando J Martinez, MD, MS
CONTACT
E
Elizabeth Peters, BSN
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here